US20100068719A1 - Cell culture system for determinging the sensitizing, allergenic and/or irritating effect of a substance - Google Patents
Cell culture system for determinging the sensitizing, allergenic and/or irritating effect of a substance Download PDFInfo
- Publication number
- US20100068719A1 US20100068719A1 US12/556,274 US55627409A US2010068719A1 US 20100068719 A1 US20100068719 A1 US 20100068719A1 US 55627409 A US55627409 A US 55627409A US 2010068719 A1 US2010068719 A1 US 2010068719A1
- Authority
- US
- United States
- Prior art keywords
- cell culture
- immune cells
- culture system
- cells
- compartment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000004113 cell culture Methods 0.000 title claims abstract description 65
- 239000000126 substance Substances 0.000 title claims abstract description 64
- 230000002009 allergenic effect Effects 0.000 title claims abstract description 31
- 230000000622 irritating effect Effects 0.000 title claims abstract description 18
- 230000001235 sensitizing effect Effects 0.000 title claims abstract description 18
- 210000002865 immune cell Anatomy 0.000 claims abstract description 90
- 210000002615 epidermis Anatomy 0.000 claims abstract description 60
- 239000011229 interlayer Substances 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 38
- 239000013566 allergen Substances 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 23
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 13
- 210000002510 keratinocyte Anatomy 0.000 claims description 12
- 210000004698 lymphocyte Anatomy 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 6
- 239000010410 layer Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 210000002540 macrophage Anatomy 0.000 claims description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 239000002973 irritant agent Substances 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 210000000438 stratum basale Anatomy 0.000 claims description 3
- 210000000434 stratum corneum Anatomy 0.000 claims description 3
- 210000000498 stratum granulosum Anatomy 0.000 claims description 3
- 210000000439 stratum lucidum Anatomy 0.000 claims description 3
- 210000000437 stratum spinosum Anatomy 0.000 claims description 3
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 11
- 238000001994 activation Methods 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 230000007815 allergy Effects 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 239000002085 irritant Substances 0.000 description 5
- 231100000021 irritant Toxicity 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000006854 communication Effects 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000003860 topical agent Substances 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102000017954 Nuclear factor of activated T cells (NFAT) Human genes 0.000 description 1
- 108050007058 Nuclear factor of activated T cells (NFAT) Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007860 molecular communication Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- -1 radical oxygen compounds Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
Definitions
- Allergy is a disorder of the immune system that is inclusive of atopy. Allergic reactions occur in response to environmental substances known as allergens; these reactions are acquired, predictable and rapid. Allergy is characterized by excessive activation of certain white blood cells, called mast cells, and basophils by a type of antibody, known as IgE, resulting in an extreme inflammatory response. Common allergic reactions include eczema, hives, hay fever, asthma, food allergies, and reactions to the venom of stinging insects such as wasps and bees.
- Inhaled allergens include dust or aerosols, e.g., pollen or house dust.
- Food allergens are substances contained in food to which the body reacts by hypersensitization (allergic reactions).
- Medicinal product allergens comprise certain active substances in medicinal products, for example antibiotics or analgesics.
- a particularly important group of allergenic substances are the contact allergens. These can cause an allergic reaction in those affected through skin contact. Certain metals and odoriferous substances belong among the contact allergens.
- the present invention relates generally to a cell culture system for determining the sensitizing, allergenic and/or irritating effect of various substances.
- the present invention is directed to a cell culture system for determining the sensitizing, allergenic and/or irritating effect of substances, comprising: a) a first compartment comprising an epidermis model; and b) a second compartment comprising a cell culture based on immune cells, wherein the first and second compartments are separated by a permeable interlayer, and wherein an allergen or irritating agent introduced into the first compartment activates the immune cells of the second compartment.
- the immune cells are antigen presenting cells, e.g., macrophages and/or dendritic cells.
- the immune cells are lymphocytes, in particular B lymphocytes and/or T lymphocytes.
- the immune cells show matching tissue compatibility antigens.
- the immune cell culture is substantially free of tissue cells.
- the immune cells are derived from a human.
- the immune cells are isolated from blood.
- the epidermis model has a layered structure.
- the epidermis model is multilayered, e.g., the epidermis model can comprise at least one epidermis layer selected from the group consisting of: stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum and stratum basale.
- the epidermis model comprises live epidermis cells, e.g., keratinocytes. In a particular embodiment, the epidermis model is substantially free of immune cells. In a particular embodiment, the epidermis model is an animal epidermis model, e.g., a human epidermis model. In a particular embodiment, the one or more substances comprise at least one cosmetic agents. In a particular embodiment, the one or more substances comprise at least one pharmacologically active medicinal agent. In a particular embodiment, the second compartment is filled with an aqueous medium.
- the present invention is directed to a method of using any of the cell culture systems described herein to examine the sensitizing, allergenic or irritating effect of one or more substances, comprising contacting the first compartment with the substance and detecting an allergenic response in the second compartment.
- the present invention is directed to a method for examining the sensitizing, allergenic and/or irritating effect of an agent, comprising: a) contacting the surface of an epidermis model contained in a first compartment with the agent; and b) determining the activity of a cell culture of immune cells contained in a second compartment, wherein the first compartment and second compartment are separated by a permeable interlayer, wherein the presence of an activated immune cell in the second compartment indicates that the agent is an allergen or irritating agent.
- the immune cells are isolated from blood.
- the cell culture comprises antigen presenting cells and lymphocytes.
- the antigen presenting cells are derived from monocytes under differentiating conditions.
- the activity of the immune cells is determined by examining the supernatant of the cell culture. In a particular embodiment, the activity of the immune cells is determined by assaying for substances produced by activated immune cells. In a particular embodiment, the substances produced by activated immune cells are selected from the group consisting of: signal transducers, receptors, enzymes and antibodies. In a particular embodiment, the activity of the immune cells is determined by assaying for messenger substances from keratinocytes of the epidermis model. In a particular embodiment, the activity of the immune cells is determined by identifying proliferation of the immune cells. In a particular embodiment, the activity of the immune cells is determined by measuring surface markers of the immune cells.
- the activity of the immune cells is determined by measuring signal transduction components of the immune cells. In a particular embodiment, the activity of the immune cells is determined by measuring intracellular cytokines of the immune cells. In a particular embodiment, the activity of the immune cells is determined by analyzing messenger RNA levels within the immune cells.
- an “allergen” is a non-parasitic antigen capable of stimulating a hypersensitivity reaction in individuals. Described herein are materials and methods that satisfactorily mimic the complex physiological situation in a subject, e.g., a human, that can lead to an allergy, while avoiding the disadvantage known from the current state of the art, but at the same time giving consideration to the current developments in the field of approval tests for cosmetics and topical agents.
- a cell culture system useful for investigating the sensitizing, allergenic and/or irritating effect of substances, comprising a first and a second compartment such that communication is allowed between the first and second compartment.
- the first compartment contains an epidermis model
- the second compartment contains immune cells.
- the communication between the two compartments is made possible by separating the compartments with a permeable interlayer.
- “communication” refers to molecular communication between cells of the two compartments, e.g., through passing of messengers or signaling molecules, e.g., chemokines, cytokines or sensitizing, allergenic and/or irritating substances, between the two compartments.
- the first compartment contains only the epidermis model
- the second compartment contains only the cell culture based on the immune cells.
- the invention provides a cell culture system that is primarily suitable for investigating contact allergens and irritants.
- the epidermis model of the first compartment is particularly advantageous as a model structure for natural skin.
- the epidermis model with the permeable interlayer provide a model for assessing the activity of contact allergens. If a substance is introduced into the first compartment comprising the epidermis model, and the substance is an allergen, then the substance or signals triggered by that substance will be sent to the second compartment that activate the immune cells.
- activate means any number of alterations to the state of the cell such that it mimics and in vivo activated immune cell (e.g., expansion of the immune cell population, production and/or release of specific molecular signals, change in the content of the cell surface receptors, change in gene expression patterns, and other measurable changes known to one of skill in the art).
- Activation of immune cells can be determined by assessing, for example, proliferation of immune cells and in the production and excretion of messenger substances and immunoglobulins, especially of immunglobulin E (IgE). Where the immune cells of the cell culture system have had contact with the substances to be examined, their presence in the second compartment, assuming that they are of an allergenic nature, causes the immune reaction described above to become more intensive. These processes can be recorded and evaluated to identify an allergen or the degree of allergenicity.
- IgE immunglobulin E
- the proximity of the epidermis model to the immune cells is a reflection of the natural configuration of skin and immune system.
- the immune cells of the second compartment are separated from the epidermis model in the first compartment by the interlayer. This arrangement can prevent inadvertent reactions between the epidermis model and the immune cells, which might otherwise interfere with the examination of the substances.
- the cellular epidermis model and the immune cells therefore, can be of different origin and, in particular, they can originate from different donors.
- the immune cells are antigen presenting cells (APCs), e.g., macrophages and/or dendritic cells.
- APCs are useful because they are involved in the presentation of allergens to other cells of the immune system. Allergen presentation causes allergen-specific lymphocytes to be activated. Activation of this kind manifests itself in particular as a proliferation of cells and in the production and excretion of messenger substances and immunoglobulins, especially of IgE. Allergen-specific T lymphocytes, together with the IgE, make contributions to the initial identification of or, if appropriate, to the re-identification, of allergenic substances.
- the immune cells of the second compartment can be precursor cells of APCs.
- Monocytes for example, can be considered as suitable precursor cells, if they are allowed to differentiate under specific conditions into APCs.
- One of skill in the art familiar with culturing monocytes would realize that precursor cells can be matured into cells useful in the cell culture system.
- the precursor cells can be incubated in the presence of various cytokines known to specifically induce differentiation.
- the precursor cells can be incubated, for example, to produce macrophages in the presence of M-CSF or G-CSF.
- the precursor cells can be incubated in the presence of, inter alia, GM-CSF and IL-4, or others.
- the differentiation can be implemented, for example, over a period of about 5 to about 20 days, for a period of about 7 to 18 days, or for a period of about 10 to 14 days.
- the immune cells of the second compartment can be lymphocytes, e.g., B lymphocytes and/or T lymphocytes. Both the B lymphocytes and the T lymphocytes are of importance for the initial identification and for re-identification of allergenic substances.
- the cell culture of the second compartment is one comprising APCs, B lymphocytes and T lymphocytes.
- the immune cells can exhibit, for example, matching tissue compatibility antigens (major histocompatibility complex (MHC) antigens). This makes it possible to avoid rejection responses between the immune cells. Rejection responses of this kind would otherwise make it difficult to investigate sensitizing, allergic and/or irritating responses that might be taking place. Moreover, a correct antigen presentation only takes place if the MHC antigens of the APC and of the B and T lymphocytes to be sensitized actually are identical, e.g., derived from the same donor.
- MHC major histocompatibility complex
- the cell culture of the second compartment can comprise tissue cells. Suitable tissue cells are, for example, keratinocytes and/or fibroblasts. The tissue cells can also be primary isolates. Alternatively, the cell culture of the second compartment can be substantially free of tissue cells.
- the immune cells can be derived, for example, from one donor, in particular from one and the same donor.
- the immune cells are isolated from blood, primarily from patient blood.
- the immune cells can be isolated from the blood of healthy persons or from those with a disposition for allergies.
- the cell culture system involves only cells of human origin. This makes it possible to simulate the in vivo situation of the human organism in a particularly effective manner. In this way it is possible to further enhance the validity of the results gained with the aid of the cell culture system with regard to a sensitizing, allergenic and/or irritating effect on humans.
- the cells of the cell culture system particularly the cells of the epidermis model and/or the immune cells, can be propagated as cell lines.
- the immune cells are isolated from a subject's blood.
- the immune cells can be isolated with the aid of tools and methods known in the art, particularly with the aid of centrifugation techniques.
- One centrifugation technique to be considered, for example, is density centrifugation.
- Other centrifugation techniques can also be used.
- the immune cells can be isolated by means of suitable sorting methods, for example magnetic beads and/or fluorescence-activated cell sorting (FACS) methods.
- the cellular epidermis model can comprise individual epidermis cells, e.g., keratinocytes.
- the epidermis model has a layered, e.g., a multilayered structure.
- the epidermis model can have a differentiated multilayered structure.
- the epidermis model manifests at least one epidermis layer from the stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum and stratum basale group.
- the epidermis model involves primarily living epidermis cells, in particular living keratinocytes.
- the epidermis model can consist of a corneous surface and the epidermal keratinocyte layers below it.
- the epidermis model is substantially free of immune cells.
- the epidermis model can be of animal origin, preferably of human origin.
- certain substances with the relevant potential can trigger additional reactions, particularly in keratinocytes of the epidermis model, which significantly improves the detection of incompatibility reactions.
- a “sensitizing” effect of a substance refers to the triggering of a sensitization event.
- “Sensitization” herein refers to the immune reactions to which initial contact with the substance, particularly with an allergen, gives rise in a given organism. Primarily this initially entails the activation of a few B lymphocytes and T lymphocytes, which then multiply greatly (oligoclonal primary response). At the end of this activation process, most of the lymphocytes are eliminated by the immune system. Allergen-specific memory cells are formed, however, that continue to exist over extended periods in significantly higher numbers than the original allergen-specific cells.
- An allergy arising as a result of sensitization is an excessive defense reaction of the immune system to a specific allergen, which may occur following a repeat contact with the relevant allergen.
- the excessive secondary immune reaction is caused by the many B lymphocyte and T lymphocyte memory cells with matching antigen receptors (oligoclonal secondary response). This means that this reaction is reinforced with each renewed contact with the allergen.
- an irritating effect stems from damage to tissue cells triggered by an irritant.
- tissue cells themselves release messenger substances, for example the lymphocyte activating factor interleukin-1 alpha (IL-1 ⁇ ) and the lymphocyte-derived neutrophil-activating peptide, also known as the chemokine interleukin-8 (IL-8).
- IL-1 ⁇ lymphocyte activating factor interleukin-1 alpha
- IL-8 lymphocyte-derived neutrophil-activating peptide
- the released messenger substances attract immune system cells and activate them. If the irritating effect of the irritant continues and gets stronger, tissue cells die. This in turn causes the release of intracellular constituents (in the sense of a necrotic process). This enhances the secondary activation of immune system cells.
- the effects accompanying an irritation are primarily antigen-unspecific. Primarily it is macrophages and granulocytes that are involved.
- the substance to be examined i.e., the potential allergenic agent or irritant
- the potential allergenic agent or irritant can be, for example, a plant extract and/or oil, cosmetics and/or their constituents, or pharmacologically active dermatologicals (topicals), particularly medicinal products to be applied topically to the skin and/or other constituents.
- the first compartment is designed as the upper compartment and the second compartment as the lower compartment of the cell culture system.
- the cell culture system for example, can be designed in the manner of the commercially available Transwell® systems.
- At least the second compartment can contain a watery, i.e., aqueous, medium.
- the invention is directed to a process for examining the sensitizing, allergenic and/or irritating effect of substances, especially when using the cell culture system described herein.
- a method can comprise the steps of a) addition of the substance to be examined on the surface of an epidermis model that is in communication with a cell culture based on immune cells via a permeable interlayer, and b) examination of the cell culture for a sensitizing, allergenic and/or irritating response.
- the supernatant of the cell culture can be examined, for example, to determine the activity state of the immune cells.
- Substances formed by the immune cells e.g., messenger substances, signal transducers (signal transduction molecules or signal transduction components), receptors, enzymes and/or antibodies, for example, can be examined in the cell culture supernatant (cell culture media) or as intracellular components.
- the messenger substances e.g., mediators
- the concentration of messenger substances is primarily determined in the culture supernatant and/or in the cells.
- the density of the signal transducers and/or receptors is determined, for example, on and/or in the immune cells.
- the messenger substances can be, for example, interferon- ⁇ (IFN ⁇ ), IL-4 and/or Eotaxin.
- Suitable receptors can be, for example, surface receptors.
- the receptors are surface receptors of the lymphocytes, e.g., CD25, CD69, CD152 and CD 154.
- Some examples of signal transducers are nuclear factor kappa beta (NF ⁇ ), zeta-associated protein (ZAP-70) and nuclear factor of activated T cells (NFAT).
- Potentially suitable enzymes can be, for example, phospholipases, cyclooxygenases, protein kinases, poly ADP ribose polymerase (PARP), matrix metalloproteinases (MMP), tryptases, caspases, dipeptidyl peptidases, kinases and/or other important enzymes for the generation of signals.
- the antibodies are primarily IgE or IgG4.
- the characteristics that indicate cellular activation by epidermis cells located in the epidermis model, particularly keratinocytes, can be assessed.
- Suitable investigation methods include, for example, electrophoretic processes, polymerase chain reaction (PCR), high pressure liquid chromatography (HPLC), array technologies, radiometric methods, histological staining techniques, flow cytometric methods and/or various different blotting methods.
- Electrophoretic methods include, for example, gel electrophoresis, e.g., two-dimensional polyacrylamide gel electrophoresis (2D page). Western blot analysis can also be used as a detection method. It is also possible to combine electrophoretic methods with blotting methods.
- Array technologies include, for example, the Immuno Solid-phase Allergen Chip (ISAC).
- Antibodies formed by the immune cells can be detected by means of appropriate immunoassays.
- immunoassays include, for example, enzyme-linked immunosorbent assay (ELISA) and radio allergosorbent test (RAST).
- Detection of secreted compounds can be accomplished by determining the concentration of the secreted substances in the supernatant of the cell culture. Techniques for detecting secreted substances are known to one of skill in the art. Secreted substances can be detected at the transcriptional level, the translational level and/or the post-translational level. The excreted substances can be examined with the aid of array technologies, especially with the aid of, for example, multiplex bead arrays or planar arrays.
- Determining the activation state of immune cells can be accomplished, for example, by detecting proliferation of the immune cells, particularly lymphocytes.
- a first or repeated contact with an allergen particularly stimulates the B lymphocytes and T lymphocytes to proliferate.
- the cell culture system described herein assesses the severity of allergenicity exhibited by a potential allergen.
- Methods described herein for identifying allergens can be quantitative.
- the data collected from various antigens/allergens can be compiled, for example, to determine a reference scale of allergenicity.
- the severity of an allergenic response is determined by a model allergenic response, with the severity determined by measuring the factors described herein, e.g., cell expansion, detection of released factors, etc. Comparing the allergenic reaction produced by a potential allergen to the reference allergenic scale, for example, allows one of skill in the art to determine the degree of allergenicity caused by the potential allergen.
- the present invention refers to the use of the cell culture system according to the invention for examining the sensitizing, allergenic and/or irritating effect of substances.
- the cell culture system according to the invention is suitable for discriminating between an allergy triggered by the examined substances and irritation.
- the cell culture system according to the invention is suitable for performing parallel examinations using multiple cell culture systems.
- keratinocytes skin material obtained by surgical means is subjected to an enzymatic digestion process. Keratinocytes, for example, gained in this manner are then transferred to membrane-bottomed dishes (e.g., Millipore Millicells®) that serve as compartments. These culture vessels contain an appropriate culture medium containing fetal calf serum, penicillin, streptomycin, non-essential amino acids and growth factors for cultivating keratinocytes. The culture medium is regularly refreshed during the culturing of the cells until sufficient three-dimensional differentiation into an epidermis equivalent has taken place.
- the differentiated epidermis encompasses multiple cell layers, particularly proliferating, non-proliferating and corneous cell layers.
- leukocytes for example, are obtained from the peripheral blood of a subject.
- the cells are enriched via a Ficoll gradient.
- the leukocytes are then propagated in multiwell plates, which serve as compartments.
- Each multiwell plate contains a suitable proliferation medium that shows necessary additives such as, for example, plasma or serum, vitamins, and/or other essential components such as, for example, amino acids, nucleotides and antibiotics (e.g., penicillin, streptomycin, etc.).
- the compartments with the differentiated epidermis cultures are fitted into the compartments with the leukocyte cultures, forming a cell culture system.
- the cell culture system is a co-culture with two different cell populations (e.g., epidermis cells and leukocytes), whereby the compartment with the epidermis culture represents the upper compartment and the compartment with the leukocytes the lower compartment.
- a substance e.g., a potentially allergenic agent or irritant
- the co-culture is then incubated for a specific time.
- the mediator synthesis of the lymphocytes and/or the parameters of the cell activation of the leukocytes in the lower compartment are measured. Additionally, the upper compartment can be examined for parameters for an irritation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
- This application claims priority to U.S. Provisional Application No. 61/095,834 filed Sep. 10, 2008, the entire disclosure of which is incorporated herein by reference.
- Allergy is a disorder of the immune system that is inclusive of atopy. Allergic reactions occur in response to environmental substances known as allergens; these reactions are acquired, predictable and rapid. Allergy is characterized by excessive activation of certain white blood cells, called mast cells, and basophils by a type of antibody, known as IgE, resulting in an extreme inflammatory response. Common allergic reactions include eczema, hives, hay fever, asthma, food allergies, and reactions to the venom of stinging insects such as wasps and bees.
- Different types of allergens are known. Inhaled allergens include dust or aerosols, e.g., pollen or house dust. Food allergens are substances contained in food to which the body reacts by hypersensitization (allergic reactions). Medicinal product allergens comprise certain active substances in medicinal products, for example antibiotics or analgesics. A particularly important group of allergenic substances are the contact allergens. These can cause an allergic reaction in those affected through skin contact. Certain metals and odoriferous substances belong among the contact allergens.
- In recent decades, especially in the Western industrial countries a sudden rise in the number of allergens has been observed. Many allergenic substances are ingredients of cosmetics or other topically applied substances (compositions for local external application). Cosmetics or topical agents are tested for their allergenic properties by means of experiments on animals. The findings thus gained, however, are only of limited value because experimental animals do not always react to the same allergens as human beings and vice versa. This situation frequently gives rise to false positive and false negative results. Meanwhile there are also practical and ethical concerns associated with animal testing.
- In light of the state of testing for allergenic activity, there is a need for effective new tools and methods for determining allergenic activity.
- The present invention relates generally to a cell culture system for determining the sensitizing, allergenic and/or irritating effect of various substances.
- In one embodiment, the present invention is directed to a cell culture system for determining the sensitizing, allergenic and/or irritating effect of substances, comprising: a) a first compartment comprising an epidermis model; and b) a second compartment comprising a cell culture based on immune cells, wherein the first and second compartments are separated by a permeable interlayer, and wherein an allergen or irritating agent introduced into the first compartment activates the immune cells of the second compartment. In a particular embodiment, the immune cells are antigen presenting cells, e.g., macrophages and/or dendritic cells. In a particular embodiment, the immune cells are lymphocytes, in particular B lymphocytes and/or T lymphocytes. In a particular embodiment, the immune cells show matching tissue compatibility antigens. In a particular embodiment, the immune cell culture is substantially free of tissue cells. In a particular embodiment, the immune cells are derived from a human. In a particular embodiment, the immune cells are isolated from blood. In a particular embodiment, the epidermis model has a layered structure. In a particular embodiment, the epidermis model is multilayered, e.g., the epidermis model can comprise at least one epidermis layer selected from the group consisting of: stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum and stratum basale. In a particular embodiment, the epidermis model comprises live epidermis cells, e.g., keratinocytes. In a particular embodiment, the epidermis model is substantially free of immune cells. In a particular embodiment, the epidermis model is an animal epidermis model, e.g., a human epidermis model. In a particular embodiment, the one or more substances comprise at least one cosmetic agents. In a particular embodiment, the one or more substances comprise at least one pharmacologically active medicinal agent. In a particular embodiment, the second compartment is filled with an aqueous medium.
- In one embodiment, the present invention is directed to a method of using any of the cell culture systems described herein to examine the sensitizing, allergenic or irritating effect of one or more substances, comprising contacting the first compartment with the substance and detecting an allergenic response in the second compartment.
- In one embodiment, the present invention is directed to a method for examining the sensitizing, allergenic and/or irritating effect of an agent, comprising: a) contacting the surface of an epidermis model contained in a first compartment with the agent; and b) determining the activity of a cell culture of immune cells contained in a second compartment, wherein the first compartment and second compartment are separated by a permeable interlayer, wherein the presence of an activated immune cell in the second compartment indicates that the agent is an allergen or irritating agent. In a particular embodiment, the immune cells are isolated from blood. In a particular embodiment, the cell culture comprises antigen presenting cells and lymphocytes. In a particular embodiment, the antigen presenting cells are derived from monocytes under differentiating conditions. In a particular embodiment, the activity of the immune cells is determined by examining the supernatant of the cell culture. In a particular embodiment, the activity of the immune cells is determined by assaying for substances produced by activated immune cells. In a particular embodiment, the substances produced by activated immune cells are selected from the group consisting of: signal transducers, receptors, enzymes and antibodies. In a particular embodiment, the activity of the immune cells is determined by assaying for messenger substances from keratinocytes of the epidermis model. In a particular embodiment, the activity of the immune cells is determined by identifying proliferation of the immune cells. In a particular embodiment, the activity of the immune cells is determined by measuring surface markers of the immune cells. In a particular embodiment, the activity of the immune cells is determined by measuring signal transduction components of the immune cells. In a particular embodiment, the activity of the immune cells is determined by measuring intracellular cytokines of the immune cells. In a particular embodiment, the activity of the immune cells is determined by analyzing messenger RNA levels within the immune cells.
- The present invention is directed to providing an extracorporeal investigation model specifically for allergens. As used herein, an “allergen” is a non-parasitic antigen capable of stimulating a hypersensitivity reaction in individuals. Described herein are materials and methods that satisfactorily mimic the complex physiological situation in a subject, e.g., a human, that can lead to an allergy, while avoiding the disadvantage known from the current state of the art, but at the same time giving consideration to the current developments in the field of approval tests for cosmetics and topical agents.
- Described herein is a cell culture system useful for investigating the sensitizing, allergenic and/or irritating effect of substances, comprising a first and a second compartment such that communication is allowed between the first and second compartment. The first compartment contains an epidermis model, and the second compartment contains immune cells. The communication between the two compartments is made possible by separating the compartments with a permeable interlayer. As used herein, “communication” refers to molecular communication between cells of the two compartments, e.g., through passing of messengers or signaling molecules, e.g., chemokines, cytokines or sensitizing, allergenic and/or irritating substances, between the two compartments. It in one embodiment, the first compartment contains only the epidermis model, and the second compartment contains only the cell culture based on the immune cells.
- The invention provides a cell culture system that is primarily suitable for investigating contact allergens and irritants. For this purpose the epidermis model of the first compartment is particularly advantageous as a model structure for natural skin. In such a situation, the epidermis model with the permeable interlayer provide a model for assessing the activity of contact allergens. If a substance is introduced into the first compartment comprising the epidermis model, and the substance is an allergen, then the substance or signals triggered by that substance will be sent to the second compartment that activate the immune cells. As used herein, “activate” means any number of alterations to the state of the cell such that it mimics and in vivo activated immune cell (e.g., expansion of the immune cell population, production and/or release of specific molecular signals, change in the content of the cell surface receptors, change in gene expression patterns, and other measurable changes known to one of skill in the art).
- Activation of immune cells can be determined by assessing, for example, proliferation of immune cells and in the production and excretion of messenger substances and immunoglobulins, especially of immunglobulin E (IgE). Where the immune cells of the cell culture system have had contact with the substances to be examined, their presence in the second compartment, assuming that they are of an allergenic nature, causes the immune reaction described above to become more intensive. These processes can be recorded and evaluated to identify an allergen or the degree of allergenicity.
- In the cell culture system the proximity of the epidermis model to the immune cells is a reflection of the natural configuration of skin and immune system. In the cell culture system the immune cells of the second compartment are separated from the epidermis model in the first compartment by the interlayer. This arrangement can prevent inadvertent reactions between the epidermis model and the immune cells, which might otherwise interfere with the examination of the substances. The cellular epidermis model and the immune cells, therefore, can be of different origin and, in particular, they can originate from different donors.
- In one embodiment, the immune cells are antigen presenting cells (APCs), e.g., macrophages and/or dendritic cells. APCs are useful because they are involved in the presentation of allergens to other cells of the immune system. Allergen presentation causes allergen-specific lymphocytes to be activated. Activation of this kind manifests itself in particular as a proliferation of cells and in the production and excretion of messenger substances and immunoglobulins, especially of IgE. Allergen-specific T lymphocytes, together with the IgE, make contributions to the initial identification of or, if appropriate, to the re-identification, of allergenic substances.
- The immune cells of the second compartment can be precursor cells of APCs. Monocytes, for example, can be considered as suitable precursor cells, if they are allowed to differentiate under specific conditions into APCs. One of skill in the art familiar with culturing monocytes would realize that precursor cells can be matured into cells useful in the cell culture system. To achieve differentiation, for example, the precursor cells can be incubated in the presence of various cytokines known to specifically induce differentiation. The precursor cells can be incubated, for example, to produce macrophages in the presence of M-CSF or G-CSF. For the purpose of differentiation into dendritic cells, the precursor cells can be incubated in the presence of, inter alia, GM-CSF and IL-4, or others. The differentiation can be implemented, for example, over a period of about 5 to about 20 days, for a period of about 7 to 18 days, or for a period of about 10 to 14 days.
- The immune cells of the second compartment can be lymphocytes, e.g., B lymphocytes and/or T lymphocytes. Both the B lymphocytes and the T lymphocytes are of importance for the initial identification and for re-identification of allergenic substances. In one embodiment, the cell culture of the second compartment is one comprising APCs, B lymphocytes and T lymphocytes.
- The immune cells can exhibit, for example, matching tissue compatibility antigens (major histocompatibility complex (MHC) antigens). This makes it possible to avoid rejection responses between the immune cells. Rejection responses of this kind would otherwise make it difficult to investigate sensitizing, allergic and/or irritating responses that might be taking place. Moreover, a correct antigen presentation only takes place if the MHC antigens of the APC and of the B and T lymphocytes to be sensitized actually are identical, e.g., derived from the same donor.
- The cell culture of the second compartment can comprise tissue cells. Suitable tissue cells are, for example, keratinocytes and/or fibroblasts. The tissue cells can also be primary isolates. Alternatively, the cell culture of the second compartment can be substantially free of tissue cells.
- The immune cells can be derived, for example, from one donor, in particular from one and the same donor. In a particular embodiment, the immune cells are isolated from blood, primarily from patient blood. The immune cells can be isolated from the blood of healthy persons or from those with a disposition for allergies.
- In a particular embodiment, the cell culture system involves only cells of human origin. This makes it possible to simulate the in vivo situation of the human organism in a particularly effective manner. In this way it is possible to further enhance the validity of the results gained with the aid of the cell culture system with regard to a sensitizing, allergenic and/or irritating effect on humans. The cells of the cell culture system, particularly the cells of the epidermis model and/or the immune cells, can be propagated as cell lines.
- In one embodiment, the immune cells are isolated from a subject's blood. In particular, the immune cells can be isolated with the aid of tools and methods known in the art, particularly with the aid of centrifugation techniques. One centrifugation technique to be considered, for example, is density centrifugation. Other centrifugation techniques, however, can also be used. Alternatively, the immune cells can be isolated by means of suitable sorting methods, for example magnetic beads and/or fluorescence-activated cell sorting (FACS) methods.
- The cellular epidermis model can comprise individual epidermis cells, e.g., keratinocytes. The epidermis model has a layered, e.g., a multilayered structure. In particular, the epidermis model can have a differentiated multilayered structure. In a further version the epidermis model manifests at least one epidermis layer from the stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum and stratum basale group. The epidermis model involves primarily living epidermis cells, in particular living keratinocytes. The epidermis model can consist of a corneous surface and the epidermal keratinocyte layers below it. In a particular embodiment, the epidermis model is substantially free of immune cells. The epidermis model can be of animal origin, preferably of human origin.
- In addition to assessing the effect of substances on the activation of immune cells, certain substances with the relevant potential can trigger additional reactions, particularly in keratinocytes of the epidermis model, which significantly improves the detection of incompatibility reactions.
- As used herein, a “sensitizing” effect of a substance refers to the triggering of a sensitization event. “Sensitization” herein refers to the immune reactions to which initial contact with the substance, particularly with an allergen, gives rise in a given organism. Primarily this initially entails the activation of a few B lymphocytes and T lymphocytes, which then multiply greatly (oligoclonal primary response). At the end of this activation process, most of the lymphocytes are eliminated by the immune system. Allergen-specific memory cells are formed, however, that continue to exist over extended periods in significantly higher numbers than the original allergen-specific cells.
- An allergy arising as a result of sensitization is an excessive defense reaction of the immune system to a specific allergen, which may occur following a repeat contact with the relevant allergen. By contrast with primary sensitization, the excessive secondary immune reaction is caused by the many B lymphocyte and T lymphocyte memory cells with matching antigen receptors (oligoclonal secondary response). This means that this reaction is reinforced with each renewed contact with the allergen.
- By contrast, an irritating effect stems from damage to tissue cells triggered by an irritant. In a first phase of irritation the tissue cells themselves release messenger substances, for example the lymphocyte activating factor interleukin-1 alpha (IL-1α) and the lymphocyte-derived neutrophil-activating peptide, also known as the chemokine interleukin-8 (IL-8). The released messenger substances attract immune system cells and activate them. If the irritating effect of the irritant continues and gets stronger, tissue cells die. This in turn causes the release of intracellular constituents (in the sense of a necrotic process). This enhances the secondary activation of immune system cells. The effects accompanying an irritation are primarily antigen-unspecific. Primarily it is macrophages and granulocytes that are involved.
- The substance to be examined, i.e., the potential allergenic agent or irritant, can be, for example, a plant extract and/or oil, cosmetics and/or their constituents, or pharmacologically active dermatologicals (topicals), particularly medicinal products to be applied topically to the skin and/or other constituents.
- In a further version the first compartment is designed as the upper compartment and the second compartment as the lower compartment of the cell culture system. The cell culture system, for example, can be designed in the manner of the commercially available Transwell® systems. At least the second compartment can contain a watery, i.e., aqueous, medium.
- In a particular embodiment, the invention is directed to a process for examining the sensitizing, allergenic and/or irritating effect of substances, especially when using the cell culture system described herein. Such a method can comprise the steps of a) addition of the substance to be examined on the surface of an epidermis model that is in communication with a cell culture based on immune cells via a permeable interlayer, and b) examination of the cell culture for a sensitizing, allergenic and/or irritating response.
- The supernatant of the cell culture can be examined, for example, to determine the activity state of the immune cells. Substances formed by the immune cells, e.g., messenger substances, signal transducers (signal transduction molecules or signal transduction components), receptors, enzymes and/or antibodies, for example, can be examined in the cell culture supernatant (cell culture media) or as intracellular components. The messenger substances (e.g., mediators) can be, for example, cytokines and/or chemokines. The concentration of messenger substances is primarily determined in the culture supernatant and/or in the cells. The density of the signal transducers and/or receptors is determined, for example, on and/or in the immune cells. The messenger substances can be, for example, interferon-γ (IFNγ), IL-4 and/or Eotaxin. Suitable receptors can be, for example, surface receptors. The receptors are surface receptors of the lymphocytes, e.g., CD25, CD69, CD152 and CD 154. Some examples of signal transducers are nuclear factor kappa beta (NFκβ), zeta-associated protein (ZAP-70) and nuclear factor of activated T cells (NFAT). Potentially suitable enzymes can be, for example, phospholipases, cyclooxygenases, protein kinases, poly ADP ribose polymerase (PARP), matrix metalloproteinases (MMP), tryptases, caspases, dipeptidyl peptidases, kinases and/or other important enzymes for the generation of signals. The antibodies are primarily IgE or IgG4.
- The characteristics that indicate cellular activation by epidermis cells located in the epidermis model, particularly keratinocytes, can be assessed. Suitable investigation methods include, for example, electrophoretic processes, polymerase chain reaction (PCR), high pressure liquid chromatography (HPLC), array technologies, radiometric methods, histological staining techniques, flow cytometric methods and/or various different blotting methods. Electrophoretic methods include, for example, gel electrophoresis, e.g., two-dimensional polyacrylamide gel electrophoresis (2D page). Western blot analysis can also be used as a detection method. It is also possible to combine electrophoretic methods with blotting methods. Array technologies include, for example, the Immuno Solid-phase Allergen Chip (ISAC).
- Antibodies formed by the immune cells can be detected by means of appropriate immunoassays. Examples for immunoassays include, for example, enzyme-linked immunosorbent assay (ELISA) and radio allergosorbent test (RAST).
- Substances secreted by the immune cells can also be detected to determine the state of activation of immune cells. The secreted substances can be, for example, proteins and/or peptides. The proteins can be, for example, receptors and/or proteins with enzymatic activity. The secreted substances can be, for example, glycosylated proteins and/or peptides. The secreted substances can be, for example, messenger substances. The messenger substances can be low or high molecular compounds. The messenger substances can be, for example, radical oxygen compounds, lipoid compounds, biogenic amines, cytokines, growth factors and/or chemokines, soluble receptors, or even membrane vesicles (e.g., exosomes).
- Detection of secreted compounds can be accomplished by determining the concentration of the secreted substances in the supernatant of the cell culture. Techniques for detecting secreted substances are known to one of skill in the art. Secreted substances can be detected at the transcriptional level, the translational level and/or the post-translational level. The excreted substances can be examined with the aid of array technologies, especially with the aid of, for example, multiplex bead arrays or planar arrays.
- Determining the activation state of immune cells can be accomplished, for example, by detecting proliferation of the immune cells, particularly lymphocytes. A first or repeated contact with an allergen particularly stimulates the B lymphocytes and T lymphocytes to proliferate.
- The cell culture system described herein assesses the severity of allergenicity exhibited by a potential allergen. Methods described herein for identifying allergens can be quantitative. The data collected from various antigens/allergens can be compiled, for example, to determine a reference scale of allergenicity. The severity of an allergenic response is determined by a model allergenic response, with the severity determined by measuring the factors described herein, e.g., cell expansion, detection of released factors, etc. Comparing the allergenic reaction produced by a potential allergen to the reference allergenic scale, for example, allows one of skill in the art to determine the degree of allergenicity caused by the potential allergen.
- Ultimately, the present invention refers to the use of the cell culture system according to the invention for examining the sensitizing, allergenic and/or irritating effect of substances. There is a special benefit that makes the cell culture system suitable for discriminating between an allergy triggered by the examined substances and irritation. Equally, the cell culture system according to the invention is suitable for performing parallel examinations using multiple cell culture systems.
- For preparing freshly-isolated keratinocytes, skin material obtained by surgical means is subjected to an enzymatic digestion process. Keratinocytes, for example, gained in this manner are then transferred to membrane-bottomed dishes (e.g., Millipore Millicells®) that serve as compartments. These culture vessels contain an appropriate culture medium containing fetal calf serum, penicillin, streptomycin, non-essential amino acids and growth factors for cultivating keratinocytes. The culture medium is regularly refreshed during the culturing of the cells until sufficient three-dimensional differentiation into an epidermis equivalent has taken place. The differentiated epidermis encompasses multiple cell layers, particularly proliferating, non-proliferating and corneous cell layers.
- For the preparation of the immune cells, leukocytes, for example, are obtained from the peripheral blood of a subject. The cells are enriched via a Ficoll gradient. The leukocytes are then propagated in multiwell plates, which serve as compartments. Each multiwell plate contains a suitable proliferation medium that shows necessary additives such as, for example, plasma or serum, vitamins, and/or other essential components such as, for example, amino acids, nucleotides and antibiotics (e.g., penicillin, streptomycin, etc.).
- The compartments with the differentiated epidermis cultures are fitted into the compartments with the leukocyte cultures, forming a cell culture system. The cell culture system is a co-culture with two different cell populations (e.g., epidermis cells and leukocytes), whereby the compartment with the epidermis culture represents the upper compartment and the compartment with the leukocytes the lower compartment. A substance (e.g., a potentially allergenic agent or irritant) to be examined is applied to the surface of the epidermis culture of the upper compartment. The co-culture is then incubated for a specific time. To determine the sensitizing potential the lymphocyte proliferation, the mediator synthesis of the lymphocytes and/or the parameters of the cell activation of the leukocytes in the lower compartment are measured. Additionally, the upper compartment can be examined for parameters for an irritation.
- Other embodiments will be evident to those of skill in the art. It should be understood that the foregoing detailed description is provided for clarity only and is merely exemplary. The spirit and scope of the present invention are not limited to the above examples, but are encompassed by the following claims.
Claims (34)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/556,274 US20100068719A1 (en) | 2008-09-10 | 2009-09-09 | Cell culture system for determinging the sensitizing, allergenic and/or irritating effect of a substance |
| US13/361,628 US9176116B2 (en) | 2008-09-10 | 2012-01-30 | Cell culture system for determining the sensitizing, allergenic and/or irritating effect of a substance |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9583408P | 2008-09-10 | 2008-09-10 | |
| US12/556,274 US20100068719A1 (en) | 2008-09-10 | 2009-09-09 | Cell culture system for determinging the sensitizing, allergenic and/or irritating effect of a substance |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/361,628 Continuation US9176116B2 (en) | 2008-09-10 | 2012-01-30 | Cell culture system for determining the sensitizing, allergenic and/or irritating effect of a substance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20100068719A1 true US20100068719A1 (en) | 2010-03-18 |
Family
ID=41429417
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/556,274 Abandoned US20100068719A1 (en) | 2008-09-10 | 2009-09-09 | Cell culture system for determinging the sensitizing, allergenic and/or irritating effect of a substance |
| US13/361,628 Expired - Fee Related US9176116B2 (en) | 2008-09-10 | 2012-01-30 | Cell culture system for determining the sensitizing, allergenic and/or irritating effect of a substance |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/361,628 Expired - Fee Related US9176116B2 (en) | 2008-09-10 | 2012-01-30 | Cell culture system for determining the sensitizing, allergenic and/or irritating effect of a substance |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20100068719A1 (en) |
| EP (2) | EP2735873A1 (en) |
| JP (1) | JP2012501660A (en) |
| CA (1) | CA2736485C (en) |
| DK (1) | DK2353001T3 (en) |
| ES (1) | ES2476896T3 (en) |
| WO (1) | WO2010030655A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2485816A (en) * | 2010-11-25 | 2012-05-30 | Alcyomics Ltd | In vitro model for the prediction of immunogenicity, hypersensitivity or allergenicity |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11795431B2 (en) | 2017-08-17 | 2023-10-24 | The Trustees Of Princeton University | Ultrathin interfacial layer on a hydrogel to direct its surface properties and cell adhesion |
| WO2020232283A1 (en) * | 2019-05-14 | 2020-11-19 | The Trustees Of Princeton University | In vitro cell-based replacement for the draize test |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010049115A1 (en) * | 2000-01-17 | 2001-12-06 | Collins John Kevin | Vitro model for gastrointestinal inflammation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020119173A1 (en) * | 2000-12-22 | 2002-08-29 | Lin Samuel Qcheng | Cosmetic compositions for preventing skin irritation |
-
2009
- 2009-09-09 ES ES09792367.6T patent/ES2476896T3/en active Active
- 2009-09-09 CA CA2736485A patent/CA2736485C/en not_active Expired - Fee Related
- 2009-09-09 EP EP20140155911 patent/EP2735873A1/en not_active Withdrawn
- 2009-09-09 JP JP2011526301A patent/JP2012501660A/en active Pending
- 2009-09-09 WO PCT/US2009/056348 patent/WO2010030655A1/en not_active Ceased
- 2009-09-09 DK DK09792367.6T patent/DK2353001T3/en active
- 2009-09-09 EP EP09792367.6A patent/EP2353001B1/en not_active Not-in-force
- 2009-09-09 US US12/556,274 patent/US20100068719A1/en not_active Abandoned
-
2012
- 2012-01-30 US US13/361,628 patent/US9176116B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010049115A1 (en) * | 2000-01-17 | 2001-12-06 | Collins John Kevin | Vitro model for gastrointestinal inflammation |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2485816A (en) * | 2010-11-25 | 2012-05-30 | Alcyomics Ltd | In vitro model for the prediction of immunogenicity, hypersensitivity or allergenicity |
| US9651544B2 (en) | 2010-11-25 | 2017-05-16 | Alcyomics Ltd | Predicting allergic reactions |
| US10073084B2 (en) | 2010-11-25 | 2018-09-11 | Alcyomics Ltd | Predicting allergic reactions |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010030655A1 (en) | 2010-03-18 |
| EP2353001A1 (en) | 2011-08-10 |
| DK2353001T3 (en) | 2014-07-14 |
| EP2735873A1 (en) | 2014-05-28 |
| US20120129162A1 (en) | 2012-05-24 |
| EP2353001B1 (en) | 2014-04-09 |
| CA2736485A1 (en) | 2010-03-18 |
| CA2736485C (en) | 2018-04-24 |
| US9176116B2 (en) | 2015-11-03 |
| JP2012501660A (en) | 2012-01-26 |
| ES2476896T3 (en) | 2014-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rodrigues Neves et al. | Progress on reconstructed human skin models for allergy research and identifying contact sensitizers | |
| EP2961830B1 (en) | Skin model | |
| WO2020102429A1 (en) | Microfluidic device and diagnostic methods for allergy testing based on detection of basophil activation | |
| Oh et al. | Activated leukocyte cell adhesion molecule modulates Th2 immune response in atopic dermatitis | |
| US9176116B2 (en) | Cell culture system for determining the sensitizing, allergenic and/or irritating effect of a substance | |
| CN107904278B (en) | Method for detecting influence of drug on cell proliferation | |
| Oliveria et al. | Regulatory and IgE+ B cells in allergic asthma | |
| Corsini et al. | Immunotoxicology: opportunities for non-animal test development | |
| US20180348208A1 (en) | Systems And Methods For Determining The Risk Of Severe Allergic Reaction To Allergen, And The Immunological Protection Afforded By Vaccines | |
| JP7199427B2 (en) | An ex vivo model of inflamed human skin and its use for screening anti-inflammatory compounds | |
| Coulter et al. | Measurement of CD4+ and CD8+ T-lymphocyte cytokine secretion and gene expression changes in p-phenylenediamine allergic patients and tolerant individuals | |
| ES2366971T3 (en) | TESTS OF CELLS T. | |
| Hartley et al. | Chemokine receptor 7 (CCR7)-expression and IFNγ production define vaccine-specific canine T-cell subsets | |
| US20100190155A1 (en) | Methods and kits for measurement of lymphocyte function | |
| Wachholz et al. | Detection of allergen-specific IgE antibody responses | |
| Zahid et al. | Nickel challenge up regulates CD69 expression on T lymphocyte sub-sets from patients with nickel induced contact dermatitis | |
| Guttek et al. | Zinc aspartate induces proliferation of resting and antigen-stimulated human PBMC under high-density cell culture condition | |
| Jeon et al. | Monocyte activation test (MAT) as an ethical alternative to animal testing | |
| Flores-Espinosa et al. | Evaluation of Leukocyte Chemotaxis Induced by Human Fetal Membranes in an In Vitro Model | |
| Tamehiro et al. | Assessment of Immune Responses in an Animal Model of Wheat Food Allergy via Epicutaneous Sensitization | |
| Ashhurst et al. | Immunological Assessment of Lung Responses to Inhalational Lipoprotein Vaccines Against Bacterial Pathogens | |
| Ozkan et al. | Antioxidant and anticancer activity of essential oil from Origanum onites (Lamiaceae) | |
| Packi et al. | Food Allergies and Parasites in Children. Foods 2023, 12, 2465. htps | |
| Oh MiSeon et al. | Activated leukocyte cell adhesion molecule modulates Th2 immune response in atopic dermatitis. | |
| Barragan Vazquez | Development of an immune competent human skin equivalent model of atopic dermatitis for pre-clinical drug testing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: RULES-BASED MEDICINE, INC.,TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCHMOLZ, MANFRED;REEL/FRAME:023577/0262 Effective date: 20091008 |
|
| AS | Assignment |
Owner name: COMPASS BANK, TEXAS Free format text: SECURITY AGREEMENT;ASSIGNOR:RULES-BASED MEDICINE, INC.;REEL/FRAME:025387/0906 Effective date: 20090810 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
| AS | Assignment |
Owner name: MYRIAD RBM, INC., TEXAS Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:COMPASS BANK;REEL/FRAME:041793/0474 Effective date: 20170213 |